Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > Plasminogen Improves Lung Lesions and Hypoxemia

<< Previous

Bullboard Posts

Next >>

Comment by stockbuphoonon Mar 19, 2020 11:28pm

72 Views

Post# 30829132

RE:Plasminogen Improves Lung Lesions and Hypoxemia

just imagine if Pierre had have taken the conservative approach to CMC and hired consultants in 2015 and Ryplazim was approved in 2018, they would be pumping Ryplazim into COVID19 lungs right now. Maybe trump or others might see the potential under these desperate times. Give LMNL a billion to produce as much Pg as possible? Dreaming but who knows if this pandemic gets out of control

Biostocks01 wrote:

Plasminogen Improves Lung Lesions and Hypoxemia in Patients with COVID-19
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3552628

Bio